表紙
市場調查報告書

皮膚T細胞性淋巴瘤(CTCL)- 市場洞見、流行病學、市場預測 2028年

Cutaneous T-Cell Lymphoma(CTCL) - Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 524417
出版日期 內容資訊 英文 150 Pages
商品交期: 最快1-2個工作天內
價格
皮膚T細胞性淋巴瘤(CTCL)- 市場洞見、流行病學、市場預測 2028年 Cutaneous T-Cell Lymphoma(CTCL) - Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 2020年01月01日內容資訊: 英文 150 Pages
簡介

皮膚T細胞性淋巴瘤(CTCL)是一種淋巴增生症候群,特徵是惡性T淋巴球往皮膚增生。CTCL被分類為非霍奇金氏淋巴瘤(NHL),也是統稱。皮膚T細胞性淋巴瘤(CTCL)是皮膚淋巴癌最常見的類型。被診斷為罹患皮膚淋巴癌的4人中有3人以上是CTCL,這種疾病有時會發生像是濕疹一樣的皮膚紅疹,對身體產生大範圍影響。 CTCL有各式各樣的亞型,其中最常見的類型是蕈狀肉芽腫。根據情況不同,CTCL,也就是皮膚T細胞性淋巴瘤,有可能不僅發病在皮膚,還有可能引起伴隨著感染、搔癢的腫瘤形成、剝離和潰瘍。在病程發展階段中,CTCL,也就是皮膚T細胞性淋巴瘤,會蔓延至淋巴結、內臟及末梢血管。 CTCL,也就是皮膚T細胞性淋巴瘤,並不是會危及生命的疾病,幾乎所有情況都能夠治療,但是無法完全治癒。

主要7國(美國、英國、德國、法國、義大利、西班牙、日本)在2018年罹患皮膚T細胞性淋巴瘤(CTCL)的人數是8,617人,該年的市場規模推估是7億8,524萬美元。

本報告調查了主要7國(美國、英國、德國、法國、義大利、西班牙、日本)的皮膚T細胞性淋巴瘤(CTCL)市場,並統整了疾病概要與現行治療法、已上市治療藥物及新藥檔案,主要7國的市場動向、流行病學預測、市場規模、部門別罹患人數變化及預測、unmet needs、市場成長因素及障礙等。

目錄

第1章 重要研究

第2章 皮膚T細胞性淋巴瘤(CTCL)市場概要

  • 皮膚T細胞性淋巴瘤(CTCL)的分佈(實際數值)
  • 皮膚T細胞性淋巴瘤(CTCL)的分佈(預測數值)

第3章 疾病背景與概要:皮膚T細胞性淋巴瘤(CTCL)

  • 簡介
  • 類型
  • 病期
  • 原因
  • 病狀生理
  • 症狀
  • 診斷

第4章 流行病學與患者人口

  • 主要研究結果
  • 人口與預測參數

第5章 主要7國的皮膚T細胞性淋巴瘤(CTCL)罹患人口

第6章 皮膚T細胞性淋巴瘤(CTCL)的流行病學:國別

  • 美國
    • 皮膚T細胞性淋巴瘤(CTCL)總罹病數
    • 皮膚T細胞性淋巴瘤(CTCL)罹病數:2次類型別
    • 皮膚T細胞性淋巴瘤(CTCL)罹病數:性別
    • 皮膚T細胞性淋巴瘤(CTCL)罹病數:病期別
  • EU5國
    • 德國
      • 皮膚T細胞性淋巴瘤(CTCL)總罹病數
      • 皮膚T細胞性淋巴瘤(CTCL)罹病數:2次類型別
      • 皮膚T細胞性淋巴瘤(CTCL)罹病數:性別
      • 皮膚T細胞性淋巴瘤(CTCL)罹病數:病期別
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本
    • 皮膚T細胞性淋巴瘤(CTCL)總罹病數
    • 皮膚T細胞性淋巴瘤(CTCL)罹病數:2次類型別
    • 皮膚T細胞性淋巴瘤(CTCL)罹病數:性別
    • 皮膚T細胞性淋巴瘤(CTCL)罹病數:病期別

第7章 治療演算法、現行治療

第8章 unmet needs

第9章 已上市治療藥

  • Istodax(Romidepsin):Celgene Corporation
    • 產品概述
    • 作用機制
    • 法規里程碑
    • 優缺點
    • 安全性及有效性
    • 產品檔案
  • Potelegio (Mogamulizumab):協和發酵麒麟
  • Valchlor/ Ledaga (Mechlorethamine):Actelion
  • Uvadex(Methoxsalen):Mallinckrodt Pharmaceuticals
  • Targretin (Bexarotene):衛采
  • Zolinza (Vorinostat):Merck Sharp & Dohme Corp.
  • Adcetris (Brentuximab Vedotin):Seattle Genetics

第10章 新藥

  • 第III相醫藥品分析 - 單株抗體與光線力學療法
  • 第II相醫藥品分析 - 組織蛋白去乙醯酶(HDAC)抑制劑
    • 產品概述
    • 法規里程碑
    • 臨床開發
    • 產品檔案
  • Resminostat:4SC AG
  • Remetinostat:Medivir AB

第11章 主要7國的皮膚T細胞性淋巴瘤(CTCL)市場分析

  • 主要研究結果
  • 主要7國的總市場規模
  • 主要7國的市場規模:早期
  • 主要7國的市場規模:晚期

第12章 美國市場預測

  • 美國的市場規模
    • 總市場規模
    • 早期皮膚T細胞性淋巴瘤(CTCL)市場:第一選擇藥別
    • 早期皮膚T細胞性淋巴瘤(CTCL)市場:第二選擇藥別
    • 晚期皮膚T細胞性淋巴瘤(CTCL)市場:第一選擇藥別
    • 晚期皮膚T細胞性淋巴瘤(CTCL)市場:第二選擇藥別

第13章 EU5國與日本市場的預測

  • 德國
    • 總市場規模
    • 早期皮膚T細胞性淋巴瘤(CTCL)市場:第一選擇藥別
    • 早期皮膚T細胞性淋巴瘤(CTCL)市場:第二選擇藥別
    • 晚期皮膚T細胞性淋巴瘤(CTCL)市場:第一選擇藥別
    • 晚期皮膚T細胞性淋巴瘤(CTCL)市場:第二選擇藥別
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第14章 市場的成長因素

第15章 市場障礙

第16章 附錄

第17章 調查方法

第18章 DelveInsight的服務內容

第19章 免責事項

第20章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0091

DelveInsight's "Cutaneous T-Cell Lymphoma(CTCL) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Cutaneous T-Cell Lymphoma(CTCL), historical and forecasted epidemiology as well as the Cutaneous T-Cell Lymphoma(CTCL) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Cutaneous T-Cell Lymphoma(CTCL) market report provides current treatment practices, emerging drugs, Cutaneous T-Cell Lymphoma(CTCL) market share of the individual therapies, current and forecasted Cutaneous T-Cell Lymphoma(CTCL) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Cutaneous T-Cell Lymphoma(CTCL) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Cutaneous T-Cell Lymphoma(CTCL) Disease Understanding and Treatment Algorithm

The DelveInsight Cutaneous T-Cell Lymphoma(CTCL) market report gives a thorough understanding of the Cutaneous T-Cell Lymphoma(CTCL) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Cutaneous T-Cell Lymphoma(CTCL).

Treatment

It covers the details of conventional and current medical therapies available in the Cutaneous T-Cell Lymphoma(CTCL) market for the treatment of the condition. It also provides Cutaneous T-Cell Lymphoma(CTCL) treatment algorithms and guidelines in the United States, Europe, and Japan.

Cutaneous T-Cell Lymphoma(CTCL) Epidemiology

The Cutaneous T-Cell Lymphoma(CTCL) epidemiology division provide insights about historical and current Cutaneous T-Cell Lymphoma(CTCL) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Cutaneous T-Cell Lymphoma(CTCL) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Cutaneous T-Cell Lymphoma(CTCL) Epidemiology

The epidemiology segment also provides the Cutaneous T-Cell Lymphoma(CTCL) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Cutaneous T-Cell Lymphoma(CTCL) Drug Chapters

Drug chapter segment of the Cutaneous T-Cell Lymphoma(CTCL) report encloses the detailed analysis of Cutaneous T-Cell Lymphoma(CTCL) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Cutaneous T-Cell Lymphoma(CTCL) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Cutaneous T-Cell Lymphoma(CTCL) treatment.

Cutaneous T-Cell Lymphoma(CTCL) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Cutaneous T-Cell Lymphoma(CTCL) treatment.

Cutaneous T-Cell Lymphoma(CTCL) Market Outlook

The Cutaneous T-Cell Lymphoma(CTCL) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Cutaneous T-Cell Lymphoma(CTCL) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Cutaneous T-Cell Lymphoma(CTCL) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Cutaneous T-Cell Lymphoma(CTCL) market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Cutaneous T-Cell Lymphoma(CTCL) market in 7MM.

The United States Market Outlook

This section provides the total Cutaneous T-Cell Lymphoma(CTCL) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Cutaneous T-Cell Lymphoma(CTCL) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Cutaneous T-Cell Lymphoma(CTCL) market size and market size by therapies in Japan is also mentioned.

Cutaneous T-Cell Lymphoma(CTCL) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Cutaneous T-Cell Lymphoma(CTCL) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Cutaneous T-Cell Lymphoma(CTCL) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Cutaneous T-Cell Lymphoma(CTCL) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Cutaneous T-Cell Lymphoma(CTCL) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Cutaneous T-Cell Lymphoma(CTCL) emerging therapies.

Reimbursement Scenario in Cutaneous T-Cell Lymphoma(CTCL)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Cutaneous T-Cell Lymphoma(CTCL) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Cutaneous T-Cell Lymphoma(CTCL) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Cutaneous T-Cell Lymphoma(CTCL) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Cutaneous T-Cell Lymphoma(CTCL), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Cutaneous T-Cell Lymphoma(CTCL) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Cutaneous T-Cell Lymphoma(CTCL) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Cutaneous T-Cell Lymphoma(CTCL) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Cutaneous T-Cell Lymphoma(CTCL) market

Report Highlights

  • In the coming years, Cutaneous T-Cell Lymphoma(CTCL) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Cutaneous T-Cell Lymphoma(CTCL) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Cutaneous T-Cell Lymphoma(CTCL). Launch of emerging therapies will significantly impact the Cutaneous T-Cell Lymphoma(CTCL) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Cutaneous T-Cell Lymphoma(CTCL)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Cutaneous T-Cell Lymphoma(CTCL) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Cutaneous T-Cell Lymphoma(CTCL) Pipeline Analysis
  • Cutaneous T-Cell Lymphoma(CTCL) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Cutaneous T-Cell Lymphoma(CTCL) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Cutaneous T-Cell Lymphoma(CTCL) Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Cutaneous T-Cell Lymphoma(CTCL) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Cutaneous T-Cell Lymphoma(CTCL) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Cutaneous T-Cell Lymphoma(CTCL) total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Cutaneous T-Cell Lymphoma(CTCL) market size during the forecast period (2017-2030)?
  • At what CAGR, the Cutaneous T-Cell Lymphoma(CTCL) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Cutaneous T-Cell Lymphoma(CTCL) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Cutaneous T-Cell Lymphoma(CTCL) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Cutaneous T-Cell Lymphoma(CTCL)?
  • What is the historical Cutaneous T-Cell Lymphoma(CTCL) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Cutaneous T-Cell Lymphoma(CTCL) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Cutaneous T-Cell Lymphoma(CTCL)?
  • Out of all 7MM countries, which country would have the highest prevalent population of Cutaneous T-Cell Lymphoma(CTCL) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Cutaneous T-Cell Lymphoma(CTCL) treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Cutaneous T-Cell Lymphoma(CTCL) in the USA, Europe, and Japan?
  • What are the Cutaneous T-Cell Lymphoma(CTCL) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Cutaneous T-Cell Lymphoma(CTCL)?
  • How many therapies are developed by each company for Cutaneous T-Cell Lymphoma(CTCL) treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Cutaneous T-Cell Lymphoma(CTCL) treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Cutaneous T-Cell Lymphoma(CTCL) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Cutaneous T-Cell Lymphoma(CTCL) and their status?
  • What are the key designations that have been granted for the emerging therapies for Cutaneous T-Cell Lymphoma(CTCL)?
  • What are the global historical and forecasted market of Cutaneous T-Cell Lymphoma(CTCL)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Cutaneous T-Cell Lymphoma(CTCL) market
  • To understand the future market competition in the Cutaneous T-Cell Lymphoma(CTCL) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Cutaneous T-Cell Lymphoma(CTCL) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Cutaneous T-Cell Lymphoma(CTCL) market
  • To understand the future market competition in the Cutaneous T-Cell Lymphoma(CTCL) market

Table of Contents

1. Key Insights

2. Executive Summary of Cutaneous T-Cell Lymphoma(CTCL)

3. Competitive Intelligence Analysis for Cutaneous T-Cell Lymphoma(CTCL)

4. Cutaneous T-Cell Lymphoma(CTCL): Market Overview at a Glance

  • 4.1. Cutaneous T-Cell Lymphoma(CTCL) Total Market Share (%) Distribution in 2017
  • 4.2. Cutaneous T-Cell Lymphoma(CTCL) Total Market Share (%) Distribution in 2030

5. Cutaneous T-Cell Lymphoma(CTCL): Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Cutaneous T-Cell Lymphoma(CTCL) Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Cutaneous T-Cell Lymphoma(CTCL) Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Cutaneous T-Cell Lymphoma(CTCL) Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Cutaneous T-Cell Lymphoma(CTCL) Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Cutaneous T-Cell Lymphoma(CTCL) Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Cutaneous T-Cell Lymphoma(CTCL) Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Cutaneous T-Cell Lymphoma(CTCL) Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Cutaneous T-Cell Lymphoma(CTCL) Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Cutaneous T-Cell Lymphoma(CTCL) Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Cutaneous T-Cell Lymphoma(CTCL) Treatment and Management
  • 8.2. Cutaneous T-Cell Lymphoma(CTCL) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Cutaneous T-Cell Lymphoma(CTCL) Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Cutaneous T-Cell Lymphoma(CTCL): Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Cutaneous T-Cell Lymphoma(CTCL) Market Size in 7MM
  • 13.3. Cutaneous T-Cell Lymphoma(CTCL) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Cutaneous T-Cell Lymphoma(CTCL) Total Market Size in the United States
    • 15.1.2. Cutaneous T-Cell Lymphoma(CTCL) Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Cutaneous T-Cell Lymphoma(CTCL) Total Market Size in Germany
    • 15.3.2. Cutaneous T-Cell Lymphoma(CTCL) Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Cutaneous T-Cell Lymphoma(CTCL) Total Market Size in France
    • 15.4.2. Cutaneous T-Cell Lymphoma(CTCL) Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Cutaneous T-Cell Lymphoma(CTCL) Total Market Size in Italy
    • 15.5.2. Cutaneous T-Cell Lymphoma(CTCL) Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Cutaneous T-Cell Lymphoma(CTCL) Total Market Size in Spain
    • 15.6.2. Cutaneous T-Cell Lymphoma(CTCL) Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Cutaneous T-Cell Lymphoma(CTCL) Total Market Size in the United Kingdom
    • 15.7.2. Cutaneous T-Cell Lymphoma(CTCL) Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Cutaneous T-Cell Lymphoma(CTCL) Total Market Size in Japan
    • 15.8.3. Cutaneous T-Cell Lymphoma(CTCL) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Cutaneous T-Cell Lymphoma(CTCL)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Tables

  • Table 1 : 7MM Cutaneous T-Cell Lymphoma(CTCL) Epidemiology (2017-2030)
  • Table 2 : 7MM Cutaneous T-Cell Lymphoma(CTCL) Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Cutaneous T-Cell Lymphoma(CTCL) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Cutaneous T-Cell Lymphoma(CTCL) Epidemiology in Germany (2017-2030)
  • Table 6 : Cutaneous T-Cell Lymphoma(CTCL) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Cutaneous T-Cell Lymphoma(CTCL) Epidemiology in France (2017-2030)
  • Table 8 : Cutaneous T-Cell Lymphoma(CTCL) Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Cutaneous T-Cell Lymphoma(CTCL) Epidemiology in Italy (2017-2030)
  • Table 10 : Cutaneous T-Cell Lymphoma(CTCL) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Cutaneous T-Cell Lymphoma(CTCL) Epidemiology in Spain (2017-2030)
  • Table 12 : Cutaneous T-Cell Lymphoma(CTCL) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Cutaneous T-Cell Lymphoma(CTCL) Epidemiology in the UK (2017-2030)
  • Table 14 : Cutaneous T-Cell Lymphoma(CTCL) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Cutaneous T-Cell Lymphoma(CTCL) Epidemiology in Japan (2017-2030)
  • Table 16 : Cutaneous T-Cell Lymphoma(CTCL) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Cutaneous T-Cell Lymphoma(CTCL) Epidemiology (2017-2030)
  • Figure 2 : 7MM Cutaneous T-Cell Lymphoma(CTCL) Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Cutaneous T-Cell Lymphoma(CTCL) Epidemiology in the United States (2017-2030)
  • Figure 4 : Cutaneous T-Cell Lymphoma(CTCL) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Cutaneous T-Cell Lymphoma(CTCL) Epidemiology in Germany (2017-2030)
  • Figure 6 : Cutaneous T-Cell Lymphoma(CTCL) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Cutaneous T-Cell Lymphoma(CTCL) Epidemiology in France (2017-2030)
  • Figure 8 : Cutaneous T-Cell Lymphoma(CTCL) Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Cutaneous T-Cell Lymphoma(CTCL) Epidemiology in Italy (2017-2030)
  • Figure 10 : Cutaneous T-Cell Lymphoma(CTCL) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Cutaneous T-Cell Lymphoma(CTCL) Epidemiology in Spain (2017-2030)
  • Figure 12 : Cutaneous T-Cell Lymphoma(CTCL) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Cutaneous T-Cell Lymphoma(CTCL) Epidemiology in the UK (2017-2030)
  • Figure 14 : Cutaneous T-Cell Lymphoma(CTCL) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Cutaneous T-Cell Lymphoma(CTCL) Epidemiology in Japan (2017-2030)
  • Figure 16 : Cutaneous T-Cell Lymphoma(CTCL) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)